Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.Read MoreSickle Cell Anemia, Crispr (DNA), Food and Drug Administration, Vertex Pharmaceuticals Inc, CRISPR Therapeutics, Clinical Trials, Genetic Engineering, Drugs (Pharmaceuticals)NYT > Health